We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best immunology stocks on our list.
TheFly reported on May 18 that a federal jury in the U.S. District Court for the District of Massachusetts determined that Takeda Pharmaceutical Company violated U.S. antitrust laws by engaging in an agreement that delayed the introduction of a generic version of its Amitiza medication. The case centered on claims that the company improperly restricted market competition through a so-called “pay-for-delay” arrangement with a rival manufacturer. As a result of the verdict, the jury ordered TAK to pay substantial monetary damages amounting to several hundred million dollars.
In a separate move, on May 4, Takeda Pharmaceutical Company Limited (NYSE:TAK) announced that its pivotal Phase 2/3 clinical study, TAK-881-3001, successfully achieved its primary endpoint in patients with primary immunodeficiency disease. The trial evaluated pharmacokinetic performance and demonstrated that TAK-881, a high-concentration subcutaneous immunoglobulin therapy facilitated with recombinant hyaluronidase, was comparable to the established HYQVIA treatment in terms of drug exposure.
Secondary outcomes indicated similar safety, efficacy, and tolerability profiles between the two therapies, with no new safety concerns identified. The results also suggested that TAK-881 may enable effective immune protection while reducing infusion volume and time, potentially offering a more convenient dosing experience for patients. The study included both adult and pediatric participants and supports continued development of TAK-881 as a next-generation immunoglobulin therapy, with additional analyses ongoing and regulatory submissions planned across major global markets in 2026.
Takeda Pharmaceutical Company Limited (NYSE:TAK) is a global biopharmaceutical company headquartered in Tokyo and Osaka, Japan. Founded in 1781, it is Japan’s largest pharmaceutical firm and ranks among the top 20 globally.
While we acknowledge the risk and potential of TAK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TAK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .
Disclosure: None. Follow Insider Monkey on Google News.
